Importer of Controlled Substances; Notice of Application; Noramco, Inc., 31388 [2012-12825]
Download as PDF
<![CDATA[
31388
Federal Register / Vol. 77, No. 102 / Friday, May 25, 2012 / Notices
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 25, 2012.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in Schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: May 15, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–12828 Filed 5–24–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application; Noramco, Inc.
Pursuant to Title 21 Code of Federal
Regulations § 1301.34(a), this is notice
that on August 18, 2011, Noramco, Inc.,
500 Swedes Landing Road, Wilmington,
Delaware 19801–4417, made application
by renewal to the Drug Enforcement
Administration (DEA) for registration as
an importer of the following basic
classes of controlled substances:
Drug
mstockstill on DSK4VPTVN1PROD with NOTICES
[FR Doc. 2012–12825 Filed 5–24–12; 8:45 am]
II
II
II
II
BILLING CODE P
Jkt 226001
The company plans to import the
listed controlled substance in finished
dosage form (FDF) from foreign sources
for analytical testing and clinical trials
in which the foreign FDF will be
compared to the company’s own
domestically manufactured FDF. This
analysis is required to allow the
company to export domestically
manufactured FDF to foreign markets.
In reference to the import of Fentanyl
(9801), the authorization for the import
of this basic class of controlled
substance is granted only for analytical
testing and clinical trials. This
authorization does not extend to the
import of a finished FDA approved or
non-approved dosage form for
commercial distribution in the United
States.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Capricorn Pharma, Inc., to import the
basic class of controlled substance is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Capricorn Pharma, Inc.,
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above named
company is granted registration as an
importer of the basic class of controlled
substance listed.
Dated: May 15, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–12824 Filed 5–24–12; 8:45 am]
DEPARTMENT OF JUSTICE
The company plans to import the raw
Opium (9600) and Poppy Straw
Concentrate (9670) to manufacture other
controlled substances. The company
plans to import Tapentadol (9780) in
intermediate form for the bulk
manufacture of Tapentadol (9780)
which it will distribute to its customers.
The company plans to import the
Phenylacetone (8501) in bulk for the
manufacture of a controlled substance.
Comments and requests for hearings
on applications to import narcotic raw
material are not appropriate. 72 FR 3417
(2007).
17:55 May 24, 2012
Dated: May 15, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Schedule
Phenylacetone (8501) ..................
Opium, raw (9600) .......................
Poppy Straw Concentrate (9670)
Tapentadol (9780) ........................
VerDate Mar<15>2010
In regard to the non-narcotic raw
material, any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 25, 2012.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e), and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975, 40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
BILLING CODE 4410–09–P
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration; Capricorn
Pharma, Inc.
By Notice dated March 8, 2012, and
published in the Federal Register on
March 20, 2012, 77 FR 16262, Capricorn
Pharma, Inc., 6900 English Muffin Way,
Unit A, Frederick, Maryland 21703,
made application to the Drug
Enforcement Administration (DEA) to
be registered as an importer of Fentanyl
(9801), a basic class of controlled
substance listed in schedule II.
PO 00000
Frm 00099
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration; Meridian
Medical Technologies
By Notice dated March 23, 2012, and
published in the Federal Register on
April 2, 2012, 77 FR 19716, Meridian
Medical Technologies, 2555 Hermelin
Drive, St. Louis, Missouri 63144, made
application by renewal to the Drug
Enforcement Administration (DEA) to
E:\FR\FM\25MYN1.SGM
25MYN1
]]>Agencies
[Federal Register Volume 77, Number 102 (Friday, May 25, 2012)]
[Notices]
[Page 31388]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-12825]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application;
Noramco, Inc.
Pursuant to Title 21 Code of Federal Regulations Sec. 1301.34(a),
this is notice that on August 18, 2011, Noramco, Inc., 500 Swedes
Landing Road, Wilmington, Delaware 19801-4417, made application by
renewal to the Drug Enforcement Administration (DEA) for registration
as an importer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Phenylacetone (8501)....................... II
Opium, raw (9600).......................... II
Poppy Straw Concentrate (9670)............. II
Tapentadol (9780).......................... II
------------------------------------------------------------------------
The company plans to import the raw Opium (9600) and Poppy Straw
Concentrate (9670) to manufacture other controlled substances. The
company plans to import Tapentadol (9780) in intermediate form for the
bulk manufacture of Tapentadol (9780) which it will distribute to its
customers. The company plans to import the Phenylacetone (8501) in bulk
for the manufacture of a controlled substance.
Comments and requests for hearings on applications to import
narcotic raw material are not appropriate. 72 FR 3417 (2007).
In regard to the non-narcotic raw material, any bulk manufacturer
who is presently, or is applying to be, registered with DEA to
manufacture such basic classes of controlled substances listed in
schedule I or II, which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the
circumstances set forth in 21 U.S.C. 958(i), file comments or
objections to the issuance of the proposed registration and may, at the
same time, file a written request for a hearing on such application
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR
1316.47.
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than June 25, 2012.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR Sec. 1301.34(b),
(c), (d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import a basic class of any controlled substances
in schedule I or II are, and will continue to be, required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: May 15, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-12825 Filed 5-24-12; 8:45 am]
BILLING CODE P
